 Patients will be treated with gemcitabine and Orathecin rubitecan capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase versus gemcitabine and placebo of the study. Toxicity of the drug combination will also be evaluated. 